Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
NCT04298853Phase 4Completed
- Sponsor
- Indiana University
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of morphine in neonatal abstinence syndrome (NAS) (2 arms), sponsored by Indiana University. Primary endpoints: Enrollment Rate at 4 hours, Drop Out Rate at 6 weeks and 1 more. Started Jun 2020; status: completed.
02
Drugs
morphine
03
Conditions
neonatal abstinence syndrome (NAS)
Beyond the preview
Go deeper on NCT04298853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298853.